Centiva Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Centiva Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,872	Closed	-$166K	–	1915
2023 Q3	$166K	Buy	+14,872	New	+$240K	﹤0.01%	1426

Other funds holding ENTA

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Centiva Capital's ENTA Position: Q4 2023 in Review

Centiva Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 14,872 shares — an estimated $166K sold.

Centiva Capital first reported a position in ENTA in Q3 2023 and held it in 1 quarter. The position peaked at $166K in Q3 2023. 106 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Centiva Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Centiva Capital sold 14,872 Enanta Pharmaceuticals shares in Q4 2023, an estimated $166K.
Centiva Capital first reported a position in Enanta Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Centiva Capital's Enanta Pharmaceuticals position peaked at $166K in Q3 2023.
106 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.